Scholar Rock Holding Corporation
scholarrock.comWhat Do They Do?
Develops antibody medicines for people with spinal muscular atrophy and other rare neuromuscular diseases.
10-K for FY2025, filed Mar 3, 2026We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and…View ↗
Apitegromab is a novel, investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro-…View ↗
Our clinical-stage pipeline also includes SRK-439, a novel, investigational, subcutaneously administered fully human anti-pro/latent…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$109.9MView ↗
- ▼ 0% (Loss)
- vs −$110M in Q2 FY2025
-
Sep 11, 2026
FDA approves ISEMBYLD for spinal muscular atrophy
The U.S. launch is underway, with product available to ship in the coming days.
Sources
8-K, filed Sep 14, 2026
On September 11, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug…View ↗
Narrower therapeutic focus
The older report described programs spanning neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The latest report centers the strategy on rare neuromuscular diseases and seeks partners for its cancer, fibrosis, and anemia programs.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 3, 2026Based on this proprietary and scalable technology platform, we are building a growing portfolio of novel product candidates with the aim of…View ↗
Who Do They Compete With?
Competes with Roche, Biogen, NMD Pharma, Novartis, AbbVie, Bicara Therapeutics, Bristol Myers Squibb, and Merck
10-K for FY2025, filed Mar 3, 2026We are developing apitegromab, an investigational fully human monoclonal antibody designed to inhibit myostatin activation by selectively…View ↗
Loading...
